Published • loading... • Updated
Amgen Details Phase 3 Sleep Apnea Studies for Investigational Drug MariTide
Summary by sleepreviewmag.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Amgen Details Phase 3 Sleep Apnea Studies for Investigational Drug MariTide
The company shared updates on its MARITIME-OSA clinical trials, evaluating a new antibody-peptide conjugate for adults with obstructive sleep apnea and overweight or obesity. Key takeaways: Amgen is enrolling participants in two phase 3 studies, MARITIME-OSA-1 and MARITIME-OSA-2, for its investigational drug MariTide. The trials will evaluate the monthly injection in adults with moderate to severe obstructive sleep apnea who are living with ove…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
